Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiyen Biotech CoTPE:1737 +0.93%81 Debt-to-EBITDA is 0.36 as of Jun. 2026, which is 12% below its 10-year median of 0.41. GuruFocus rates TPE:1737 with a GF Score™ of 81/100 and a GF Value™ of NT$31.18 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,556 Consumer Packaged Goods companies, Taiyen Biotech Co ranks better than 84.32% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Taiyen Biotech Co's Debt-to-EBITDA or its related term are showing as below:
TPE:1737'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.1 Med: 0.41 Max: 0.72
Current: 0.31
During the past 13 years, the highest Debt-to-EBITDA Ratio of Taiyen Biotech Co was 0.72. The lowest was 0.10. And the median was 0.41.
TPE:1737's Debt-to-EBITDA is ranked better than 84.32% of 1556
companies
in the Consumer Packaged Goods industry
Industry Median: 2.125
vs TPE:1737: 0.31
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Taiyen Biotech Co Debt-to-EBITDA Related Terms
Taiyen Biotech Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Taiyen Biotech Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1737 vs PG, CL, KVUE: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, Taiyen Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Taiyen Biotech Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Taiyen Biotech Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Taiyen Biotech Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Taiyen Biotech Co (TPE:1737) has a Debt-to-EBITDA of 0.36 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiyen Biotech Co. This is 12% below median its historical median of 0.41. Over the past decade, Taiyen Biotech Co's Debt-to-EBITDA has ranged from 0.10 to 0.72. According to the industry distribution chart, Taiyen Biotech Co ranks #244 out of 1556 companies in the Consumer Packaged Goods industry, placing it in the top 15.7%.
Is Taiyen Biotech Co's Debt-to-EBITDA too high?
Taiyen Biotech Co's current Debt-to-EBITDA of 0.36 is 12% below median its 10-year median of 0.41. Over the past 10 years, this metric has ranged from a low of 0.10 to a high of 0.72. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.13. Taiyen Biotech Co's value of 0.36 is 83.1% below this industry median. Based on the distribution chart, Taiyen Biotech Co ranks #244 out of 1556 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Taiyen Biotech Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Taiyen Biotech Co's Debt-to-EBITDA compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Taiyen Biotech Co ranks #244 out of 1556 companies for Debt-to-EBITDA. This places Taiyen Biotech Co in the top 16% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 2.13. Taiyen Biotech Co's value of 0.36 is 83.1% below this benchmark. Historically, Taiyen Biotech Co's own Debt-to-EBITDA has ranged from 0.10 to 0.72 over the past decade. While the company's 10-year median is 0.41 vs. the industry median of 2.13, Taiyen Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.13, based on 1,556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Taiyen Biotech Co's current Debt-to-EBITDA of 0.36 is 83.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Taiyen Biotech Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiyen Biotech Co's current Debt-to-EBITDA is 0.36, which is 12% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiyen Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Taiyen Biotech Co (TPE:1737) is currently considered Fairly Valued. The stock's GF Value™ is NT$31.18, compared to a current price of NT$32.40 — trading 3.9% above its estimated fair value. The current Debt-to-EBITDA is 0.36, which is 12% below median its 10-year median of 0.41 and 83.1% below the Consumer Packaged Goods industry median of 2.13. Taiyen Biotech Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Taiyen Biotech Co (TPE:1737), the current Debt-to-EBITDA is 0.36 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiyen Biotech Co (TPE:1737) Overvalued in 2026?
Based on GuruFocus' analysis, Taiyen Biotech Co stock appears to be overvalued.
The current stock price of NT$32.40 is trading 3.9% above its estimated GF Value™ of NT$31.18.
GuruFocus considers Taiyen Biotech Co to be Fairly Valued.
Key valuation signals for TPE:1737:
Debt-to-EBITDA: 0.36 (12% below median its 10-year median of 0.41)
GF Value™: NT$31.18 vs. price of NT$32.40 (3.9% above fair value)
Industry Position: 83.1% below the Consumer Packaged Goods median (#244 of 1556)
No single metric tells the full story. See the TPE:1737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiyen Biotech Co Ltd operates in personal care and home care products. Its product portfolio comprises beauty care products, health food, skin products, salt products and spices, bottled water, and medical supplies, among others. The group has four reportable segments; Salt products and packaged water department, Biotech cleaning and maintenance department, Construction and services department, and Other departments.. The Salt and Packaged Product Segment accounts for the bulk of revenue. Geographically it operates through the region of Taiwan; however, it also holds a presence in the international market.
81GF Score
Get the complete analysis for TPE:1737
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1737 has been successfully added to your 
